Trial Profile
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2018
Price :
$35
*
At a glance
- Drugs Heparin/lidocaine/sodium-bicarbonate (Primary) ; Heparin; Lidocaine
- Indications Interstitial cystitis
- Focus Therapeutic Use
- Acronyms Engage 24
- Sponsors Urigen
- 09 Jul 2018 Status changed from recruiting to discontinued.
- 01 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 01 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.